Sodium-glucose cotransporter-2 inhibitor luseogliflozin added to glucagon-like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes: A 52-week, open-label, single-arm study.
Yutaka SeinoDaisuke YabeTakashi SasakiAtsushi FukatsuHisae ImazekiHidekazu OchiaiSoichi SakaiPublished in: Journal of diabetes investigation (2017)
Luseogliflozin added to liraglutide was well tolerated, and improved glycemic control with bodyweight and fat mass reductions in Japanese type 2 diabetes patients.